

## 6. Anhang

### 6.1. Literaturverzeichnis

1. Braunwald, E, Morrow, AG Cornell, WP. Idiopathic hypertrophic subaortic stenosis: Clinical, hemodynamic and angiographic manifestaions. Am J Med, 1960. 29(924).
2. Morrow, AG Braunwald, E. Functional aortic stenosis: A malformation characterized by resistance to left ventricular outflow without anatomic obstruction. Circulation, 1959. 20(181).
3. Braunwald, E, Lambrew, C Rockoff, SD. Idiopathic subaortic stenosis: A description of the disease based upon an anylsis of 64 patients. Circulation, 1964. 30(4): p. 113-119.
4. Criley, JM. Unobstructed thinking (and terminology) is called for in the understanding and management if hypertrophic cardiomyopathy. J Am Coll Cardiol, 1997. 29(741).
5. Spirito, P, Seidman, CE, McKenna, WJ Maron, BJ. The management of hypertrophic cardiomyopathy. N Engl J Med, 1997. 336(11): p. 775-85.
6. ACCF TASK FORCE ON CLINICAL EXPERT CONSENSUS DOCUMENTS MEMBERS. American College of Cardiology/European Society of Cardiology Clinical Expert: Consensus Document on Hypertrophic Cardiomyopathy. J Am Coll Cardiol, 2003. 42(9): p. 1687-1712.
7. Maron, BJ. Hypertrophic cardiomyopathy. Lancet, 1997. 350(9071): p. 127-33.
8. Maron, BJ, Olivotto, I, Spirito, P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation, 2000. 102(8): p. 858-64.
9. Spirito, P Maron, BJ. Sudden death and hypertrophic cardiomyopathy. Lancet, 2001. 357(9272): p. 1975-6.
10. Watkins, H. Sudden death in hypertrophic cardiomyopathy. N Engl J Med, 2000. 342(6): p. 422-4.
11. Maron, BJ, Casey, SA, Poliac, LC, et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. Jama, 1999. 281(7): p. 650-5.

12. Cecchi, F, Olivotto, I, Monteregegi, A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. *J Am Coll Cardiol*, 1995. 26(6): p. 1529-36.
13. Hecht, GM, Klues, HG, Roberts, WC Maron, BJ. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. *J Am Coll Cardiol*, 1993. 22(2): p. 489-97.
14. Maron, BJ. Hypertrophic cardiomyopathy: a systematic review. *Jama*, 2002. 287(10): p. 1308-20.
15. Solomon, SD, Jarcho, JA, McKenna, W, et al. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. *J Clin Invest*, 1990. 86(3): p. 993-9.
16. Niimura, H, Bachinski, LL, Sangwatanaroj, S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. *N Engl J Med*, 1998. 338(18): p. 1248-57.
17. Maron, BJ, Niimura, H, Casey, SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. *J Am Coll Cardiol*, 2001. 38(2): p. 315-21.
18. Marian, A. Modifier genes for hypertrophic cardiomyopathy. *Curr Opin Cardiol*, 2002. 17: p. 242-52.
19. Seidman, DS, Ever-Hadani, P Gale, R. The effect of maternal weight gain in pregnancy on birth weight. *Obstet Gynecol*, 1989. 74(2): p. 240-6.
20. Siu, BL, Niimura, H, Osborne, JA, et al. Familial dilated cardiomyopathy locus maps to chromosome 2q31. *Circulation*, 1999. 99(8): p. 1022-6.
21. Maron, BJ, Tajik, AJ, Ruttenberg, HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. *Circulation*, 1982. 65(1): p. 7-17.
22. Shirani, J, Maron, BJ, Cannon, RO, 3rd, Shahin, S Roberts, WC. Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. *Am J Cardiol*, 1993. 72(5): p. 434-40.
23. Maron, BJ, Mathenge, R, Casey, SA, Poliac, LC Longe, TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. *J Am Coll Cardiol*, 1999. 33(6): p. 1590-5.

24. Maron, BJ, Wolfson, JK, Epstein, SE Roberts, WC. Morphologic evidence for "small vessel disease" in patients with hypertrophic cardiomyopathy. *Z Kardiol*, 1987. 76 Suppl 3: p. 91-100.
25. Maron, BJ, Wolfson, JK, Epstein, SE Roberts, WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. *J Am Coll Cardiol*, 1986. 8(3): p. 545-57.
26. Cecchi, F, Olivotto, I, Monteregegi, A, et al. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. *Heart*, 1998. 79(4): p. 331-6.
27. Maron, BJ, Epstein, SE Roberts, WC. Hypertrophic cardiomyopathy: a common cause of sudden death in the young competitive athlete. *Eur Heart J*, 1983. 4 Suppl F: p. 135-44.
28. Epstein, SE Maron, BJ. Sudden death and the competitive athlete: perspectives on preparticipation screening studies. *J Am Coll Cardiol*, 1986. 7(1): p. 220-30.
29. Maron, BJ. Echocardiographic assessment of left ventricular hypertrophy in patients with obstructive or nonobstructive hypertrophic cardiomyopathy. *Eur Heart J*, 1983. 4 Suppl F: p. 73-91.
30. Maron, BJ, Bonow, RO, Seshagiri, TN, Roberts, WC Epstein, SE. Hypertrophic cardiomyopathy with ventricular septal hypertrophy localized to the apical region of the left ventricle (apical hypertrophic cardiomyopathy). *Am J Cardiol*, 1982. 49(8): p. 1838-48.
31. Maron, BJ, Gottdiener, JS Epstein, SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. *Am J Cardiol*, 1981. 48(3): p. 418-28.
32. Panza, JA Maron, BJ. Simultaneous occurrence of mitral valve prolapse and systolic anterior motion in hypertrophic cardiomyopathy. *Am J Cardiol*, 1991. 67(5): p. 404-10.
33. Sherrid, MV, Chaudhry, FA Swistel, DG. Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction. *Ann Thorac Surg*, 2003. 75(2): p. 620-32.

34. Maron, BJ Roberts, WC. Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. *Circulation*, 1979. 59(4): p. 689-706.
35. Varnava, AM, Elliott, PM, Sharma, S, McKenna, WJ Davies, MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. *Heart*, 2000. 84(5): p. 476-82.
36. Jacob, R, Dierberger, B Kissling, G. Functional significance of the Frank-Starling mechanism under physiological and pathophysiological conditions. *Eur Heart J*, 1992. 13 Suppl E: p. 7-14.
37. Baan, J, van der Velde, ET, de Bruin, HG, et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. *Circulation*, 1984. 70(5): p. 812-23.
38. Georgakopoulos, D Kass, D. Minimal force-frequency modulation of inotropy and relaxation of in situ murine heart. *J Physiol*, 2001. 534(Pt. 2): p. 535-45.
39. Feldman, MD, Mao, Y, Valvano, JW, Pearce, JA Freeman, GL. Development of a multifrequency conductance catheter-based system to determine LV function in mice. *Am J Physiol Heart Circ Physiol*, 2000. 279(3): p. H1411-20.
40. Baan, J Van der Velde, ET. Sensitivity of left ventricular end-systolic pressure-volume relation to type of loading intervention in dogs. *Circ Res*, 1988. 62(6): p. 1247-58.
41. Georgakopoulos, D, Christe, ME, Giewat, M, et al. The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. *Nat Med*, 1999. 5(3): p. 327-30.
42. McConnell, BK, Fatkin, D, Semsarian, C, et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. *Circ Res*, 2001. 88(4): p. 383-9.
43. Semsarian, C, Ahmad, I, Giewat, M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. *J Clin Invest*, 2002. 109(8): p. 1013-20.
44. Maron, MS, Olivotto, I, Betocchi, S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. *N Engl J Med*, 2003. 348(4): p. 295-303.
45. Zile, MR Brutsaert, DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. *Circulation*, 2002. 105(12): p. 1503-8.

46. Zile, MR, Baicu, CF, Gaasch, WH. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med*, 2004. 350(19): p. 1953-9.
47. East, JM. Sarco(endo)plasmic reticulum calcium pumps: recent advances in our understanding of structure/function and biology (review). *Mol Membr Biol*, 2000. 17(4): p. 189-200.
48. Landesberg, A, Sideman, S. Mechanical regulation of cardiac muscle by coupling calcium kinetics with cross-bridge cycling: a dynamic model. *Am J Physiol*, 1994. 267(2 Pt 2): p. H779-95.
49. Gilligan, DM, Chan, WL, Joshi, J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. *J Am Coll Cardiol*, 1993. 21(7): p. 1672-9.
50. Kass, DA, Wolff, MR, Ting, CT, et al. Diastolic compliance of hypertrophied ventricle is not acutely altered by pharmacologic agents influencing active processes. *Ann Intern Med*, 1993. 119(6): p. 466-73.
51. Begley, DA, Mohiddin, SA, Tripodi, D, Winkler, JB, Fananapazir, L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. *Pacing Clin Electrophysiol*, 2003. 26(9): p. 1887-96.
52. Elliott, P, McKenna, WJ. Hypertrophic cardiomyopathy. *Lancet*, 2004. 363(9424): p. 1881-91.
53. Miller, T, Szczesna, D, Housmans, PR, et al. Abnormal contractile function in transgenic mice expressing a familial hypertrophic cardiomyopathy-linked troponin T (I79N) mutation. *J Biol Chem*, 2001. 276(6): p. 3743-55.
54. Tschope, C, Westermann, D, Steendijk, P, et al. Hemodynamic characterization of left ventricular function in experimental coxsackieviral myocarditis: effects of carvedilol and metoprolol. *Eur J Pharmacol*, 2004. 491(2-3): p. 173-9.
55. Walther, T, Steendijk, P, Westermann, D, et al. Angiotensin deficiency in mice leads to dilated cardiomyopathy. *Eur J Pharmacol*, 2004. 493(1-3): p. 161-5.
56. Steendijk, P, Staal, E, Jukema, JW, Baan, J. Hypertonic saline method accurately determines parallel conductance for dual-field conductance catheter. *Am J Physiol Heart Circ Physiol*, 2001. 281(2): p. H755-63.

57. Lavoie, JL, Lake-Bruse, KD Sigmund, CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. *Am J Physiol Renal Physiol*, 2004. 286(5): p. F965-71.
58. Tschöpe, C, Walther, T, Koniger, J, et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. *Faseb J*, 2004. 18(7): p. 828-35.
59. Wu, JC, Chen, IY, Wang, Y, et al. Molecular Imaging of the Kinetics of Vascular Endothelial Growth Factor Gene Expression in Ischemic Myocardium. *Circulation*, 2004.
60. Kass, DA, Hare, JM Georgakopoulos, D. Murine cardiac function: a cautionary tail. *Circ Res*, 1998. 82(4): p. 519-22.
61. Baan, J, Jong, TT, Kerkhof, PL, et al. Continuous stroke volume and cardiac output from intra-ventricular dimensions obtained with impedance catheter. *Cardiovasc Res*, 1981. 15(6): p. 328-34.
62. Baan, J, van der Velde, ET Steendijk, P. Ventricular pressure-volume relations in vivo. *Eur Heart J*, 1992. 13 Suppl E: p. 2-6.
63. Feldman, MD, Erikson, JM, Mao, Y, et al. Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals. *Am J Physiol Heart Circ Physiol*, 2000. 279(4): p. H1698-707.
64. Georgakopoulos, D, Mitzner, WA, Chen, CH, et al. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. *Am J Physiol*, 1998. 274(4 Pt 2): p. H1416-22.
65. Kass, DA, Midei, M, Graves, W, Brinker, JA Maughan, WL. Use of a conductance (volume) catheter and transient inferior vena caval occlusion for rapid determination of pressure-volume relationships in man. *Cathet Cardiovasc Diagn*, 1988. 15(3): p. 192-202.
66. Wallace, A, Lam, HW Mangano, DT. Linearity, load dependence, hysteresis, and clinical associations of systolic and diastolic indices of left ventricular function in man. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. *J Card Surg*, 1995. 10(4 Suppl): p. 460-7.
67. Wang, Q, Brunner, HR Burnier, M. Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter. *Am J Physiol Heart Circ Physiol*, 2004. 286(2): p. H806-14.

68. Wodey, E, Chonow, L, Beneux, X, et al. Haemodynamic effects of propofol vs thiopental in infants: an echocardiographic study. *Br J Anaesth*, 1999. 82(4): p. 516-20.
69. Janssen, BJ, De Celle, T, Debets, JJ, et al. Effects of anesthetics on systemic hemodynamics in mice. *Am J Physiol Heart Circ Physiol*, 2004.
70. Knollmann, BC, Blatt, SA, Horton, K, et al. Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy. *J Biol Chem*, 2001. 276(13): p. 10039-48.
71. Knollmann, BC, Potter, JD. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. *Trends Cardiovasc Med*, 2001. 11(5): p. 206-12.
72. Sweeney, HL, Feng, HS, Yang, Z, Watkins, H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. *Proc Natl Acad Sci U S A*, 1998. 95(24): p. 14406-10.
73. Montgomery, DE, Tardiff, JC, Chandra, M. Cardiac troponin T mutations: correlation between the type of mutation and the nature of myofilament dysfunction in transgenic mice. *J Physiol*, 2001. 536(Pt 2): p. 583-92.
74. Szczesna, D, Zhang, R, Zhao, J, et al. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. *J. Biol. Chem.*, 2000. 275: p. 624–630.
75. Tardiff, JC, Factor, SM, Tompkins, BD, et al. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. *J Clin Invest*, 1998. 101(12): p. 2800-11.
76. Kass, DA, Bronzwaer, JG, Paulus, WJ. What mechanisms underlie diastolic dysfunction in heart failure? *Circ Res*, 2004. 94(12): p. 1533-42.
77. Yamamoto, K, Masuyama, T, Sakata, Y, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. *Cardiovasc Res*, 2002. 55(1): p. 76-82.
78. Cingolani, OH, Yang, XP, Cavaasin, MA, Carretero, OA. Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. *Hypertension*, 2003. 41(2): p. 249-54.
79. Zile, MR, Brutsaert, DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. *Circulation*, 2002. 105(11): p. 1387-93.

80. Knollmann, BC, Kirchhof, P, Sirenko, SG, et al. Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca<sup>2+</sup>-dependent action potential remodeling. *Circ Res*, 2003. 92(4): p. 428-36.
81. Braunwald, E. Braunwald: Heart Failure 6th. Edition. Textbook, 2000. 6th Edition.
82. Varma, SK, Owen, RM, Smucker, ML Feldman, MD. Is tau a preload-independent measure of isovolumetric relaxation? *Circulation*, 1989. 80(6): p. 1757-65.
83. Maron, BJ, Roberts, WC, McAllister, HA, Rosing, DR Epstein, SE. Sudden death in young athletes. *Circulation*, 1980. 62(2): p. 218-29.
84. Maron, BJ, Epstein, SE Roberts, WC. Causes of sudden death in competitive athletes. *J Am Coll Cardiol*, 1986. 7(1): p. 204-14.
85. Lüllmann, H Mohr, K. Pharmakologie und Toxikologie. Textbook, 1999. 14th Edition.
86. Yeager, JC Whitehurst, ME. Verapamil prevents isoproterenol-induced cardiac failure in the rat. *Life Sci*, 1982. 30(3): p. 299-306.